Research
Hormonal
Tirzepatide (15 mg) demonstrates superior weight loss efficacy compared to semaglutide (1 mg) in patients with type 2 diabetes, achieving 13.1% weight loss versus 9.7 kg (9.6%) for semaglutide 2.4 mg in direct comparison trials.
For patients with type 2 diabetes needing significant weight loss, tirzepatide (15 mg weekly) has shown higher weight loss percentages (13.1%) compared to semaglutide (1 mg weekly) in head-to-head trials. This requires a slow 20-week titration to manage side effects, which may impact adherence.
StrongSupportsVERY_HIGH confidence
Injection of tirzepatide at 15 mg for the same duration lowered the body weight by 13.1% in SURPASS-2 with an ETD of 6.4% compared to semaglutide 1 mg treatment.
Why this rating
Based on SURPASS-2, a large phase III randomized trial.
Source
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Han Na Jung et al. · Journal of Obesity & Metabolic Syndrome · 2022
narrative_review · n=3567Cited 31×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →